Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis

2022 ◽  
pp. annrheumdis-2021-221747
Author(s):  
Claudius Speer ◽  
Maximilian Töllner ◽  
Louise Benning ◽  
Katrin Klein ◽  
Marie Bartenschlager ◽  
...  
Keyword(s):  
Vaccine Dose ◽  
Anca Associated Vasculitis

Biologics for ANCA-Associated Vasculitis

2014 ◽  
Vol 13 (4) ◽  
pp. 275-287 ◽  
Author(s):  
Giuseppe Murgia ◽  
Davide Firinu ◽  
Paolo Manconi ◽  
Stefano Giacco
Keyword(s):  
Anca Associated Vasculitis

scholarly journals Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health

2019 ◽  
Vol 46 (10) ◽  
pp. 1415-1420 ◽  
Author(s):  
Nataliya Milman ◽  
Eilish McConville ◽  
Joanna C. Robson ◽  
Annelies Boonen ◽  
Peter Tugwell ◽  
...  
Keyword(s):  
The United States ◽  
International Classification ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Personal Factors ◽  
Disability And Health ◽  
Individual Interviews ◽  
The United Kingdom ◽  
Anca Associated Vasculitis ◽  
Core Set

Objective.Aspects of antineutrophil cytoplasmic antibodies–associated vasculitis (AAV) prioritized by patients with AAV were described using the International Classification of Function, Disability, and Health (ICF).Methods.Items identified during 14 individual interviews were incorporated into an ICF-based questionnaire administered to participants of 2 vasculitis patient symposia: 36 in the United Kingdom and 63 in the United States.Results.Categories identified as at least “moderately relevant” by ≥ 5% of subjects included 44 body functions, 14 body structures, 35 activities and participation, 31 environmental factors, and 38 personal factors.Conclusion.Identified categories differ from those identified by the current Outcome Measures in Rheumatology (OMERACT) core set and those prioritized by vasculitis experts.

Sign in / Sign up

Export Citation Format

Share Document